Novartis drug Signifor recommended by CHMP for EU approval to treat patients with Cushing's disease
24-Jan-2012 -
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® (SOM230, pasireotide) for the treatment of Cushing's disease. There are currently no approved medicines in the European Union (EU) targeting Cushing's disease, ...
cortisol
Cushing's disease
Novartis
+1